The Emerging Role of Carbon-Ion Radiotherapy by Daniel K. Ebner & Tadashi Kamada
June 2016 | Volume 6 | Article 1401
PersPective
published: 07 June 2016
doi: 10.3389/fonc.2016.00140
Frontiers in Oncology | www.frontiersin.org
Edited by: 
Marco Durante, 
GSI, Germany
Reviewed by: 
William F. Hartsell, 
Northwestern Medicine Chicago 
Proton Center, USA  
Takashi Nakano, 
Gunma University, Japan
*Correspondence:
Tadashi Kamada  
kamada.tadashi@qst.go.jp
Specialty section: 
This article was submitted 
to Radiation Oncology, 
a section of the journal 
Frontiers in Oncology
Received: 25 January 2016
Accepted: 23 May 2016
Published: 07 June 2016
Citation: 
Ebner DK and Kamada T (2016) The 
Emerging Role of Carbon-Ion 
Radiotherapy. 
Front. Oncol. 6:140. 
doi: 10.3389/fonc.2016.00140
the emerging role of carbon-ion 
radiotherapy
Daniel K. Ebner and Tadashi Kamada*
Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan
Carbon-ion radiotherapy (CIRT) has progressed rapidly in technological delivery, indi-
cations, and efficacy. Owing to a focused dose distribution in addition to high linear 
energy transfer and subsequently high relative biological effect, CIRT is uniquely able 
to target otherwise untreatable hypoxic and radioresistant disease while opening the 
door for substantially hypofractionated treatment of normal and radiosensitive disease. 
CIRT has increasingly garnered international attention and is nearing the tipping point for 
international adoption.
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iNtrODUctiON
In 1952, the first human patients were treated by John Lawrence and Cornelius Tobias with helium 
and deuteron particle beams (1). Subsequently, interest in particle beams expanded, with proton 
facilities emerging throughout the world. However, as the biological impact of protons mirrored that 
of X-ray therapy, attention turned to heavier ions due to a higher biological impact owing to higher 
linear energy transfer (LET) (2). In 1975, with the installation of the BEVALAC to the Lawrence 
Berkeley Laboratory (LBL), extensive research into the clinical potential of heavy-ion beams more 
formally began (3).
In response to the initial successes at LBL, in 1984, the Japanese government began construc-
tion on the world’s first heavy-ion facility designated for medical use at the National Institute of 
Radiological Sciences (NIRS), staffing it with scientists returning from the BEVALAC and LBL. The 
Heavy Ion Medical Accelerator in Chiba (HIMAC) was completed in 1993, with clinical trials in 
carbon-ion radiotherapy (CIRT) beginning in June 1994.
Similar to the BEVALAC, the HIMAC provided for passive-beam irradiation. NIRS was alone in 
offering CIRT until 1997, when the GSI Carbon-Ion Radiotherapy Facility in Germany came into 
operation, pioneering raster scanning heavy-ion beams in clinical practice. GSI treated 440 patients 
with good results before its closure in 2008 (4). NIRS completed development of a pencil-beam raster 
scanning (PBS) treatment facility in 2012, and initial clinical trials are promising.
Developments in diagnostic technologies have enabled new therapeutic applications, such as 
markerless respiration-gated PBS irradiation. The enhanced radiobiological effect of the carbon-
ion, concentrated and converged into a highly conformal dose distribution coinciding with target-
respiratory movement, has allowed for medical care of radioresistant, previously untreatable disease 
(5–7). Further, these advantages have provided for hypofractionated radiotherapy of more com-
mon diseases, as well as improved adverse effect profiles, in comparison to conventional therapy. 
Altogether, this has lead to excellent treatment results in numerous diseases.
To date, nearly 70 protocols have been conducted at NIRS to delineate CIRT efficacy, safety, opti-
mal treatment indications, and dose fractionation (8). Protocols begin with phase I dose-escalation 
studies focused on minimizing adverse effects. This is followed by phase II evaluation of treatment 
efficaciousness with longitudinal follow-up. If feasible, protocols exploring hypofractionation 
FiGUre 1 | Dose distribution of heavy-particle beams.
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follow. Initial protocols began with low doses and an average of 
18 fractions, but after critical review of technical and clinical data, 
today cases average 11–12 fractions. One or two total fractions 
are possible for indicated lung and liver disease, respectively. As 
such, the Hospital of the NIRS has reached a treatment capacity 
of between 900 and 1000 patients per year.
Carbon-ion radiotherapy facilities and faculty continue to 
grow in number and experience, with 8+ operational centers and 
over 15,000 patients treated to date (9). In Japan, in addition to 
the four heavy-ion radiotherapy facilities in operation prior to 
2015, the Kanagawa Cancer Center’s carbon-ion facility began 
treatment in December 2015, and plans exist to construct facili-
ties in Osaka City as well as Yamagata and Okinawa Prefectures. 
In light of the concentration of CIRT facilities in Japan, the 
Japan Carbon-ion Radiation Oncology Study Group (J-CROS) 
was organized to coordinate multi-institutional studies mov-
ing forward. Internationally, Austria will open a CIRT center 
in 2017, with centers in South Korea, Taiwan, China, and the 
United States in various states of development. Further, the clini-
cal successor to the GSI Carbon-Ion Radiotherapy Facility, the 
Heidelberg Ion Therapy Center (HIT), has begun a number of 
randomized trials, testing carbon(-boost) versus other irradia-
tion modalities (10–14).
In this paper, we aim to update on the expanding role of CIRT 
in cancer treatment as of 2016.
FeAtUres OF cirt
In comparison with conventional radiotherapy, particle beams 
possess different physical and biological characteristics that must 
be weighed when considering treatment. While conventional 
radiation generally passes continually through a biological 
target, with dose delivered roughly equivalently throughout the 
beam path, particle beams release energy at the inverse of their 
velocity (Figure  1). Particle beams thus deliver a lower entry 
dose, depositing the majority of their energy at the flight path 
terminus, yielding an asymptotic dose peak (the “Bragg Peak”) 
(15). This allows for a dose concentration distribution impossible 
with conventional irradiation methods.
Today, proton dominates particle therapy. However, the larger 
mass of carbon results in decreased beam scattering, yielding a 
sharper dose distribution border with minimal penumbra (16). 
Radiobiologically, carbon-ion beams result in two to three times 
the relative biological effect (RBE; the biological effectiveness 
of one type of ionized radiation relative to another, given the 
same amount of absorbed energy) of proton and conventional 
irradiation methods (17). In comparison with photon therapy, 
CIRT does not show an oxygen effect, sublethal damage repair, 
and has less cell-cycle-related radiosensitivity.
These unique characteristics formed the rationale in initially 
applying carbon to radioresistant and/or hypoxic disease. Further 
indications then arose: the sharp dose distribution allows thera-
peutic dose delivery to disease juxtaposed with vital, radiosensi-
tive organs (18–20). With radionormal or radiosensitive disease, 
short-term hypofractionated treatment becomes possible, owing 
to diminished dose delivered to healthy tissue.
cArBON-iON rADiOtHerAPY 
treAtMeNt
To date, over 9000 patients have undergone CIRT at NIRS, with 
12,000 across all facilities in Japan and over 15,000 worldwide. 
In 2003, upon review of the first 9 years of NIRS’ clinical trials, 
the Japanese government allowed CIRT availability to the general 
public. CIRT has demonstrated efficacy against prostate, head 
and neck, lung, and liver cancers, bone and soft tissue sarcomas, 
locally recurrent rectal cancer, and pancreatic cancer, including 
locally advanced disease (8, 19, 21). Below, we provide a brief 
summary of the current most common indications and the data 
supporting their treatment.
At NIRS, over 2000 prostate cancer patients have been treated 
with CIRT, comprising approximately a fourth of CIRT-treated 
cases. Half of these cases are considered high risk at the time of 
treatment (determined by high PSA, T3 status, or high Gleason 
score). Initially, dose escalation in 20 fractions was performed, 
followed by investigation of hypofractionation. From 2007 to 
2013, 781 patients were treated with 57.6 Gy (RBE) delivered in 
16 fractions, with 5-year overall survival (OS) and biochemical 
relapse-free rates of 96.9 and 92.8%, respectively. No grade 3 or 
higher toxicity was seen. In 2014, treatment shifted to 12 fractions 
[51.2  Gy (RBE)] delivered over 3  weeks, yielding 100% cause-
specific survival at a median follow-up of 32.3 months. At this 
dose-fractionation, no grade 3 or greater acute or late toxicities 
were observed, comparing favorably to conventional radiotherapy. 
Long-term data are pending, and further hypofractionation is 
being considered (22–24). Internationally, two randomized trials 
comparing proton and carbon are under recruitment at HIT (10).
Highly radioresistant non-squamous-cell carcinomas 
accounted for the majority of head and neck disease treated at 
NIRS, consisting of 11% of CIRT cases there. In a review of 240 
patients (243 lesions), over a 9-year period, excellent results have 
been reported. 91% of patients received 57.6 Gy (RBE) with the 
remainder receiving 64.0  Gy (RBE), both delivered in 16 frac-
tions. Approximately half of the high-dose group consisted of 
bone and soft tissue sarcomas of the head and neck. The 5-year 
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local control (LC) rate was 68% across all head and neck cancers, 
with OS of 47% (LC/OS histological breakdown: 75/35% mucosal 
malignant melanoma, 73/68% adenoid cystic carcinoma (ACC), 
73/56% adenocarcinoma, 24/36% sarcomas, 61/31% papillary 
adenocarcinoma, and 61/17% squamous cell carcinoma). Acute 
grade 3 skin and mucosal reactions were seen in 15 (6%) and 24 
(10%) of patients, respectively, with no acute grade 4 or higher 
toxicity seen. No late skin grade 3 or greater toxicities were noted. 
Late mucosal side effects included no grade 3, but four cases of 
grade 4 ipsilateral blindness (25, 26). In 109 head-and-neck-based 
malignant mucoscal melanoma patients treated concomitantly 
with dacarbazine, nimustine, and vincristine (DAV), a 5-year LC 
rate of 82% with OS of 52% was achieved versus 33% OS with 
carbon alone (27). At HIT, carbon ions were used as boost in 
ACC, achieving 78% LC at 4 years, with rates of severe late toxic-
ity <5% (28).
A majority of bone and soft tissue tumors are radioresist-
ant and form a prototypical disease for CIRT treatment. Thus, 
despite being comparatively rare, these make up 11% of CIRT 
cases at NIRS. In particular, in both the skull base and trunk, 
chordoma, osteosarcoma, spinal tumors, and retroperitoneal 
tumors treated with CIRT have demonstrated satisfactory results 
(27, 29–33). Skull base and paracervical disease treated with 
48.0–60.8 Gy (RBE) in 16 fractions yielded an overall LC and 
OS rate of 86 and 85%, respectively (LC/OS: 87/90% chordomas, 
81/76% chondrosarcomas, 89/73% olfactory neuroblastomas, 
and 83/86% meningiomas). 24.5% of patients experienced 
grade 2 or greater radiation-induced brain injury (RIBI) (7.0% 
symptomatic), with a single case of grade 4 RIBI (27, 34, 35). 
This reinforced similar results from GSI, where LC of 70% at 
5 years in chordoma and 87% at 4 years in chondrosarcomas, 
with limited toxicity, were achieved (36, 37). Randomized trials 
at HIT for these diseases are underway. In unresectable primary 
spinal sarcoma, following a dose of 52.8–70.4 Gy (RBE) in 16 
fractions, 5-year LC and OS were 79 and 52%, respectively, 
with smaller disease (<100  cm3) demonstrating 100% LC. 
Three patients (6%) experienced a grade 3 or greater adverse 
effect, and seven experienced vertebral body compression (32). 
In unresectable retroperitoneal sarcoma, following dosing of 
52.8–73.6 Gy (RBE) in 16 fractions, 5-year LC and OS was 69 
and 50%, respectively. No grade 3 or greater toxicity was noted 
(33). In unresectable truncal osteosarcoma, following a median 
70.4  Gy (RBE) applied in 16 fractions, LC of 62% and OS of 
33% was seen, with no grade 3 or greater toxicity noted. Worse 
outcomes were seen in patients with a clinical target volume 
>500 cm3 (31). At HIT, locally unresectable osteosarcomas are 
treated with carbon and chemotherapy in an ongoing trial that 
includes the only cohort of CIRT-treated pediatric patients. 
Results are forthcoming (11, 12).
With lung and liver cancers, the improved dose distribution 
and strong RBE of CIRT led to prospective trials in hypofrac-
tionation, yielding excellent results (20, 38–40). Lung cancers 
encompass 11% of cases at NIRS, and currently, single-fraction 
delivery of 50  Gy (RBE) is indicated for Stage I, T1 and T2 
non-small-cell disease. This has demonstrated a 5-year LC rate 
of 80.4% for patients receiving doses of 36.0 Gy (RBE) or more 
(T1: 86.0% and T2: 71.7%), with 5-year OS of 56.3%. For patients 
receiving 48 or 50 Gy (RBE), 2-year LC and OS were both 95% 
(39). The first non-Japanese lung cancer CIRT trial, at HIT, will 
be a prospective clinical trial on patients with chest wall infiltra-
tion (10). Hepatocellular carcinoma, making up 10% of CIRT 
indications, leads to notably poor survival rates due to inherent 
radiosensitivity of the liver combined with poor resectability (41). 
Current hypofractionation efforts led to a two-fraction regime 
consisting of 45.0 Gy (RBE). This has yielded OS and LC rates of 
71 and 83% at 3 years, respectively. No grade 3+ reactions were 
noted in a 45 Gy (RBE) or higher dose treatment group (42). Of 
note, four-fraction, 52.8-Gy (RBE) treatment of tumors lying near 
to the porta hepatis has yielded good control: 5-year LC of 87.8% 
with OS of 22.2% without similar side-effect profiles to non-porta 
hepatis cases (20). The PROMETHEUS-1 trial at HIT reported 
initial results in 2013: at 11 months, LC of 100% was achieved 
with no severe adverse events reported (43).
Locally recurrent rectal cancer (5% of cases), pancreatic 
cancer (4% of cases), and cervical adenocarcinoma and related 
cancers (gynecological tumors encompass 3% of cases) all 
demonstrate degrees of radioresistance, but CIRT has dem-
onstrated excellent performance in treating these diseases. A 
phase I/II dose-escalation study of 170 recurrent rectal cancer 
patients was performed at NIRS, with escalating dose between 
67.2 and 73.6 Gy (RBE) delivered over 16 fractions in 4 weeks. 
LC at 3 years was 92% for 73.6 Gy (RBE), with OS of 59% at 
73.6 Gy (RBE) at 5 years. No acute grade 3 or greater adverse 
events were seen, with two grade 3 late skin and one grade 3 
late gastrointestinal reaction noted (44, 45). The forthcoming 
PANDORA-01 trial at HIT will further evaluate use of carbon in 
the setting of recurrent rectal cancer (13). The results for locally 
advanced pancreatic cancer have drawn international attention 
with combined CIRT-gemcitabine therapy, yielding a 1- and 
2-year freedom from local progression rate (FFLP), evaluated 
by 18FDG uptake, of 63 and 30%, with OS at 1 and 2 years of 
73 and 35%, respectively. When limited to Stage III disease, 
2-year FFLP and OS improved to 40 and 48%, respectively. 
53% of patients experienced grade 3–4 hematological toxicity, 
and 7% experienced grade 3 anorexia. One case (1%) of grade 
3 intratumoral infection was noted. None of these reactions 
were life-threatening (21). The forthcoming PHOENIX-01 
trial at HIT will evaluate advanced pancreatic cancer treatment 
with scanning carbon-ion beam irradiation in combination 
with gemcitabine (14). With regard to cervical cancer, 58 
locally advanced adenocarcinoma cases were treated in a dose-
escalation study [62.4–74.4 Gy (RBE) in 20 fractions] between 
1998 and 2010, with 5-year LC of 54.5% and OS of 38.1%. One 
patient experienced a grade 4 rectal complication, with no other 
grade 3 or higher toxicities reported (46).
Radiotherapeutic treatment of brain malignancies remains a 
substantial challenge. Combs and colleagues conducted a pooled 
analysis of HIT and Japanese data regarding the usage of carbon-
ion boost (CIB) in the treatment of anaplastic astrocytoma (AA) 
and glioblastoma (GBM) (47–49). Postoperatively, 50-Gy photon 
with nimustine hydrochloride was administered, with 16.8–
24.8 Gy (RBE) CIRT provided as boost. In GBM and AA, median 
OS was 18 and 35 months with CIRT versus 14 and 39 months 
with standard postoperative radiochemotherapy (RCT) with 
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temozolomide. Progression-free survival of GBM and AA were 6 
and 6 months (RCT) and 8 and 34 months (CIRT), respectively. 
The potential benefit of CIRT noted is under further evaluation 
in the CLEOPATRA trial at HIT (47).
Overall, CIRT has demonstrated good adaptability for 
difficult-to-treat, radioresistant disease, while allowing accel-
erated, hypofractionated treatment of other disease. Distant 
metastasis remains a challenge, but initial evaluations of CIRT 
concurrent with chemotherapy has demonstrated satisfactory 
performance (21, 27).
FUtUre DirectiONs
The future of charged particle therapy as of 2016 appears bright, 
with implementation of respiration-gated fast PBS (50), marker-
less tracking (51), a range-shifter-free multiple-energy modula-
tion system, and completion of the second carbon-ion rotating 
gantry in the world at NIRS, following the first at Heidelberg. 
Nine plus new CIRT centers are opening worldwide. However, 
the high cost associated with the construction, maintenance, and 
operation of CIRT facilities, as well as the corresponding costs in 
staff development and support, presents a challenge for extension 
of the technology outside of the developed world.
As such, a great deal of work remains. Development in cost-
saving and improved miniaturization of existing technology is 
necessary. To date, these efforts have produced CIRT accelerator 
and synchrotrons at one-third the cost and size of the original 
HIMAC, which are in operation at the Saga-HIMAT, Gunma 
University, and Kanagawa Cancer Center i-ROCK facilities. 
Superconduction technology allowed for the recently completed 
rotating gantry at NIRS to be built with a length and diameter 
of 13 and 5.5 m, respectively, versus the existing gantry at HIT, 
which is 25  m  ×  13  m (52). Ongoing development aims to 
further employ superconducting technology in the accelerator 
and overall device, producing a total CIRT setup dubbed the 
“Super MINIMAC” that will fit within 20 m2. Meanwhile, limited 
research has been published on the cost-efficacy of CIRT (53–55), 
which would appear to improve with each new technological 
development; focused evaluation may be necessary to facilitate 
international development.
In Japan, CIRT is available as a private treatment to the general 
public. Discussion to extend national insurance coverage to CIRT 
is ongoing. However, despite the current cost burden for patients 
(3.2 million yen/~28,000 USD for a treatment course, regardless 
of fractionation; in Germany, treatment costs ~1000 Euro per 
fraction), the number of patients from both within and outside 
Japan continues to increase.
Clinically, as the majority of cases treated with CIRT in the 
world were treated at NIRS, the majority of available clinical 
data is focused at a single institution spread over 20 years (19). 
As center numbers increase, multi-institutional trials and rand-
omized, internationally coordinated trials may begin.
An international ecosystem supporting and interweaving 
CIRT clinical, physical, and biological development is also 
necessary. It is known that the LET of particle beams are non-
homogenous throughout the irradiated region, yielding varia-
tions in RBE (56). As carbon is a high LET beam, these variations 
are more appreciable than with low LET proton irradiation. Due 
to a risk of consequent under- or over-treatment and toxicity, 
complex dosing models are required in the use of heavy ions. 
Of particular note, the RBE model varies between international 
institutions. Within Japan, the MKM2010 model, a revision of the 
Microdosimetric Kinetic Model, has been developed and imple-
mented (57). In Europe, versions of the local effect model (LEM) 
are dominant. Efforts to improve international standardization 
are progressing, with work by Fossati and colleagues providing 
for MKM2010 dose translation to the LEM model and vice versa 
(58). Improved model accuracy and careful manipulation of the 
high LET/RBE regions may enable LET painting of tumors (59). 
This “intensity modulated carbon therapy” may further improve 
dose distribution, and research to this end is underway.
cONcLUsiON
Since 1970, heavy-ion radiotherapy has progressed rapidly in 
technological delivery and, consequently, in indications and 
efficacy. The ability for the carbon-ion beam to offer short-term, 
minimally invasive, function-, tissue-, and form-sparing treat-
ment has garnered international attention, with the technology 
nearing the tipping point for international adoption. Technically, 
enhanced international collaboration is needed to produce an 
intercenter translatable dosing model consensus and to enhance 
results at the common borders between radiobiology and particle 
physics. Societally, cost and access to treatment remains a chal-
lenge, particularly in developing countries. However, evidence 
continues to mount for the superiority of carbon in the treatment 
of radioresistant, hypoxic disease. Coupled with the opportunity 
for substantially abbreviated treatment of common disease, 
carbon-ion radiotherapy looks increasingly appealing as a treat-
ment modality deserving worldwide availability.
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